The trio will focus on using immune systems to attack cancer.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
The leukemia drug is staying on the market, but for a more restricted patient population.
Critics worry the talked-about approval plan could mean adverse events surface far too late.
Bernstein analyst Tim Anderson says Novartis has become a stealth player in the CDK-4/6 inhibitor competition.
Early clinical trial results indicate 81% of advanced melanoma patients survived for one year.
The drugmaker says it will not pursue regulatory review of its Phase III JAK2 inhibitor fedratinib.
The company says it will cut staff and costs, focus on big accounts and try to keep sales reps from leaving.
The regulator approved the CLL medication Friday, giving the drugmaker time to create a marketing transition before Rituxan goes generic. The approval marks another milestone: the first drug approved with a Breakthrough Designation label, a tag that is now coming under scrutiny.
The drug company is ceasing US distribution and marketing the leukemia drug after the FDA said it was worried about blood clots among clinical trial patients.
The prostate cancer drug company is reportedly seeking a buyer to turn things around.
A wide-ranging piece recounts the pushback from oncologists that led to a decrease in the price of Zaltrap.
BMS is showing signs of emerging from the cliff, but doubt lingers on Eliquis's slow launch in a post-Plavix marketplace.
Sales of its breast cancer treatments boosted totals for the first nine months of 2013, along with diagnostics, which saw a 3% increase over last year.
The drug maker is beefing up its MedImmune offerings with a $440-million acquisition and a deal with ADC Therapeutics.
The diagnostics firm is undercutting Myriad's cost by almost $1,000.
The Swiss biopharma is increasing capacity and investing $800 million in four locations.
An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.
Three former workers are accused of giving proprietary data to a drug company abroad.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.
The second-line drug sped from Priority Review status for the first-line indication to approval in just over two months.
Phase III ramucirumab hit gastric cancer goals, but failed among breast cancer patients.
Complete Response letter slows Merck's suggamedex; AbbVie looks for next Humira; Roche drug gets breakthrough label; FDA effort to better track medical devices
BI cancer drug lands breakthrough therapy designation; Sanofi tallies two European MS drug approvals; GSK terminates testing for a Crohn's drug; and Teva joins cancer collaboration
Researchers surveying 21 Long Island mammography centers found that women do not know their risk.
GlaxoSmithKline heats up the CLL category with its second breakthrough designation therapy of the year, topped off by priority review for a melanoma combo treatment.
Bristol-Myers Squibb said Thursday that the drug failed to hit its primary goal in a prostate cancer trial, but some analysts say the data is not the last word on its potential in this tumor type.